When semaglutide is administered, it binds to GLP-1 receptors that control appetite and food cravings
They are a sign that the medication is working to slow your gastric emptying, which helps you feel full longer
[175] An analysis of events in the US FDA Adverse Event Reporting System suggests an association between several GLP-1 agonists (including semaglutide) and cutaneous reactions, such as dermal hypersensitivity reactions, eosinophilic panniculitis, bullous pemphigoid, and morbilliform drug eruptions
This is not confirmed in clinical trials, but it comes up often enough in patient experience that it is worth trying if GI side effects are a problem for you
The slower pace signals fullness to your brain more quickly, creating the appetite-suppressing effect that makes weight loss easier
Each 1 mL of WEGOVY contains the following inactive ingredients: disodium phosphate dihydrate, 1.42 mg